Cell Source
Jerusalem, Israel· Est.
Innovative Veto Cell platform enabling donor‑free transplants and durable CAR‑T cancer therapies.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Innovative Veto Cell platform enabling donor‑free transplants and durable CAR‑T cancer therapies.
OncologyHematologyTransplantationAutoimmune
Technology Platform
Veto Cell technology selectively eliminates anti‑donor T‑cells, enabling immune tolerance for allogeneic transplants and enhancing CAR‑T cell persistence.
Opportunities
The Veto Cell platform can create off‑the‑shelf, donor‑agnostic transplant solutions and improve CAR‑T durability, opening large markets in HSCT, oncology, and autoimmunity.
Risk Factors
Clinical efficacy and safety uncertainties, manufacturing scale‑up, and competition from other allogeneic cell‑therapy developers pose significant execution risks.
Competitive Landscape
Cell Source differentiates through its dual Veto Cell/CAR‑T design, but faces competition from firms like Allogene, Fate Therapeutics, and other allogeneic immune‑modulation platforms.